2 fast growth ASX shares that could be buys in December 2021

Volpara is one of the ASX growth shares that could be compelling in December 2021.

| More on:
Mother and young children at doctors

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX growth shares increasing in size quickly could be contenders for an investor's portfolio.

There is growing volatility in the ASX share market. This may open up some better value opportunities for people to find.

Share prices regularly change, but lower prices give the chance getting exposure to quality companies at the best prices.

Here are two of them:

Doctor Care Anywhere Group PLC (ASX: DOC)

Doctor Care Anywhere is a UK-based telehealth company that is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence-based pathways on its platform. It has relationships with health insurers, healthcare providers and corporate customers to connect with a range of telehealth services.

It also recently completed the acquisition of Australian telehealth and tele-mental provider GP2U Telehealth. This gives the business another avenue for growth and geographical diversification. The ASX growth share has also entered the self-pay market in the Republic of Ireland through its channel partner Boots.

It's expecting to report 2021 revenue growth of at least 100% compared to FY20, excluding the acquisition.

The three months to 30 September 2021 saw growth with a number of metrics. Quarter on quarter revenue growth was 21.6% to AU$10.7 million. Consultations grew by 30.6% to 116,800 with over 65% of consultations delivered to returning patients.

Activated lives reached 603,200 during the quarter – up 8% quarter on quarter. An activated life is the total number of people who have signed up for Doctor Care Anywhere's service and entered their personal details.

Volpara Health Technologies Ltd (ASX: VHT)

Volpara describes itself as a health technology software company with an integrated platform which assists in the delivery of personalised breast care.

The ASX growth share grew its subscription revenue by 35% to NZ$11.8 million in the first half of FY22. Its revenue comes with a very high gross profit margin of 91.4%.

Its market share of women who have at least one Volpara product used on their image is around 34%.

Volpara says that its strategic commercial partnerships will help it achieve greater reach in not only genetic testing for breast cancer but expansion into the US lung cancer market where AI and software offer the prospect of saving many more lives.

It has partnered with a number of different organisations, including in lung, with RevealDx, Riverain Technologies, Natera and Invitae.

The company has a number of areas of focus for growth such as expanding the electronic health record (EHR) sales channel. It's also working on building its data platform in a key effort to change from screening for detection to prevention.

It's expecting to reach revenue of between NZ$25 million to NZ$26 million in this financial year.

Volpara management said the next few months is going to be "incredibly busy and exciting" as it heads to Chicago for the large radiology conference RSNA. The third and fourth quarters of the year are traditionally the biggest quarters for the business.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Doctor Care Anywhere Group PLC and VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia has recommended Doctor Care Anywhere Group PLC. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Growth Shares

A smiling travel agent sitting at her desk working for Corporate Travel Management
Growth Shares

My 2 best ASX growth shares to buy in November

Growth continues to catch the market's attention.

Read more »

a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
Growth Shares

Buy these ASX growth shares for 16% to 25% returns

Analysts are saying good things about these buy-rated shares.

Read more »

two children squat down in the dirt with gardening tools and a watering can wearing denim overalls and smiling very sweetly.
Growth Shares

How to maximise $10,000 by investing in 2 ASX growth shares

Here are my best growth ideas on the ASX right now.

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

These ASX 200 growth shares could rise 50% to 60%

Big returns could be on offer from these growing companies according to analysts.

Read more »

Sports fans looking at smart phone representing surging pointsbet share price
Growth Shares

Up 111% in six months, this soaring ASX share is backed to keep rising

One fund manager thinks this ASX growth share can continue its phoenix performance.

Read more »

a happy investor with a wide smile points to a graph that shows an upward trending share price
Growth Shares

These ASX growth shares are being tipped to smash the market

Returns of 14% to 68% could be on the cards for buyers of these shares according to brokers.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Growth Shares

These ASX 200 growth shares could rise 50% to 70%

Analysts are predicting these stocks to rise materially from current levels.

Read more »

A young boy sits on his father's shoulders as they flex their muscles at sunrise on a beach
Growth Shares

2 ASX 300 growth shares with 'strong momentum' this fund manager says are buys

These two stocks have plenty of growth potential, according to experts.

Read more »